Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iberdomide Combinations in R/R Aggressive B-Cell Lymphoma
NCT04882163Phase 2Withdrawn
- Sponsor
- Celgene Corporation
- Start
- Oct 2021
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of iberdomide in aggressive B-cell lymphoma, sponsored by Celgene Corporation. Planned start Oct 2021; status: withdrawn.
02
Drugs
iberdomide
03
Conditions
aggressive B-cell lymphoma
Beyond the preview
Go deeper on NCT04882163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04882163.